BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bristol Myers Squibb (BMY) announced on Friday that its drug, evaluated for myelofibrosis-associated anemia, did not meet its ...

The first half of 2025 has been topsy-turvy for Bristol Myers BMY. Shares of this biotech giant have lost 16.3% year to date compared with the industry ’s decline of 2.7%. The stock has also ...

Inflation Shock (2022) BMY stock declined 40.2% from a high of $81.13 on 2 December 2022 to $48.48 on 21 November 2023, compared to a peak-to-trough drop of 25.4% for the S&P 500 ...

PFE and BMY’s attractive dividend yield is a strong positive for investors. However, PFE’s dividend yield of 7.2% is higher than BMY’s 5.29%. Which Stock Is a Better Pick for Now?

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...